Market Closed -
Nasdaq
04:00:00 2024-07-16 pm EDT
|
5-day change
|
1st Jan Change
|
21.87
USD
|
+2.87%
|
|
+9.30%
|
-24.35%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
270.9
|
1,265
|
3,001
|
900.1
|
856.7
|
654.4
|
-
|
-
|
Enterprise Value (EV)
1 |
258.9
|
980.3
|
3,001
|
379.5
|
433.7
|
-141.2
|
-106.9
|
-74.29
|
P/E ratio
|
-645
x
|
5.85
x
|
6.14
x
|
6.43
x
|
-5.13
x
|
-8.19
x
|
-8.32
x
|
-9.51
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.33
x
|
3
x
|
3.02
x
|
1.45
x
|
2.96
x
|
2.34
x
|
2.03
x
|
1.82
x
|
EV / Revenue
|
7.96
x
|
2.32
x
|
3.02
x
|
0.61
x
|
1.5
x
|
-0.5
x
|
-0.33
x
|
-0.21
x
|
EV / EBITDA
|
53.3
x
|
3.25
x
|
4.27
x
|
1.48
x
|
288
x
|
6.03
x
|
7.77
x
|
-1,280
x
|
EV / FCF
|
61,675,894
x
|
9,415,324
x
|
-
|
1,616,672
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
-
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
3.36
x
|
2.58
x
|
-
|
0.69
x
|
0.76
x
|
0.59
x
|
0.61
x
|
0.62
x
|
Nbr of stocks (in thousands)
|
20,998
|
24,274
|
29,831
|
30,225
|
29,633
|
29,924
|
-
|
-
|
Reference price
2 |
12.90
|
52.10
|
100.6
|
29.78
|
28.91
|
21.87
|
21.87
|
21.87
|
Announcement Date
|
3/10/20
|
3/4/21
|
2/23/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
32.53
|
421.7
|
992.6
|
619
|
289.2
|
280.2
|
321.7
|
360.5
|
EBITDA
1 |
4.854
|
301.3
|
703.6
|
257.1
|
1.504
|
-23.41
|
-13.75
|
0.058
|
EBIT
1 |
-0.428
|
290.2
|
676
|
178.5
|
-195.5
|
-100
|
-96.32
|
-86.36
|
Operating Margin
|
-1.32%
|
68.8%
|
68.1%
|
28.84%
|
-67.61%
|
-35.7%
|
-29.94%
|
-23.95%
|
Earnings before Tax (EBT)
1 |
0.409
|
291.7
|
677.3
|
184
|
-174.1
|
-75.62
|
-75.05
|
-65.67
|
Net income
1 |
-0.411
|
214.3
|
507.4
|
143.4
|
-167.8
|
-71.02
|
-69.56
|
-60.09
|
Net margin
|
-1.26%
|
50.82%
|
51.12%
|
23.17%
|
-58.03%
|
-25.35%
|
-21.62%
|
-16.67%
|
EPS
2 |
-0.0200
|
8.910
|
16.38
|
4.630
|
-5.630
|
-2.670
|
-2.630
|
-2.300
|
Free Cash Flow
|
4.198
|
104.1
|
-
|
234.7
|
-
|
-
|
-
|
-
|
FCF margin
|
12.91%
|
24.69%
|
-
|
37.93%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
86.49%
|
34.56%
|
-
|
91.3%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
48.58%
|
-
|
163.7%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/4/21
|
2/23/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
251.7
|
320.3
|
125.3
|
105.7
|
67.7
|
66.17
|
67.85
|
84.69
|
70.5
|
64.48
|
69.07
|
71.82
|
74.84
|
73.48
|
79.92
|
EBITDA
1 |
159.8
|
213.4
|
31.05
|
10.17
|
-15.08
|
-7.168
|
-2.707
|
18.14
|
-6.759
|
-3.242
|
-7.441
|
-3.948
|
-8.739
|
-3.494
|
-4.4
|
EBIT
1 |
150.8
|
201.9
|
12.79
|
0.352
|
-36.55
|
-24.82
|
-19.8
|
0.214
|
-151.1
|
-21.8
|
-25.46
|
-23.15
|
-29.54
|
-24.67
|
-23.55
|
Operating Margin
|
59.93%
|
63.05%
|
10.21%
|
0.33%
|
-53.99%
|
-37.52%
|
-29.18%
|
0.25%
|
-214.34%
|
-33.8%
|
-36.86%
|
-32.23%
|
-39.47%
|
-33.57%
|
-29.46%
|
Earnings before Tax (EBT)
1 |
150.8
|
202
|
13.75
|
1.757
|
-33.46
|
-21.05
|
-14.7
|
6.86
|
-145.2
|
-14.17
|
-19.83
|
-17.61
|
-24.09
|
-19.28
|
-18.2
|
Net income
1 |
104.3
|
154
|
11.54
|
1.719
|
-23.83
|
-15.34
|
-11.23
|
-13.11
|
-128.1
|
-13.46
|
-18.25
|
-16.53
|
-23.01
|
-17.66
|
-16.58
|
Net margin
|
41.46%
|
48.08%
|
9.2%
|
1.63%
|
-35.2%
|
-23.18%
|
-16.55%
|
-15.48%
|
-181.76%
|
-20.88%
|
-26.43%
|
-23.02%
|
-30.74%
|
-24.03%
|
-20.75%
|
EPS
2 |
3.340
|
4.930
|
-
|
0.0600
|
-0.8000
|
-0.5200
|
-0.3800
|
-0.4400
|
-4.300
|
-0.4500
|
-0.7500
|
-0.7400
|
-0.7300
|
-0.7400
|
-0.6600
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/23/22
|
5/3/22
|
8/4/22
|
11/7/22
|
2/28/23
|
5/5/23
|
8/4/23
|
11/3/23
|
2/28/24
|
5/3/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
12
|
284
|
-
|
521
|
423
|
796
|
761
|
729
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
4.2
|
104
|
-
|
235
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
5.4%
|
65.7%
|
-
|
14.8%
|
-14%
|
-1.91%
|
-2.24%
|
-2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
3.840
|
20.20
|
-
|
43.00
|
38.10
|
36.80
|
36.00
|
35.20
|
Cash Flow per Share
|
-
|
5.850
|
-
|
8.190
|
-
|
-
|
-
|
-
|
Capex
1 |
1.32
|
36.5
|
-
|
18.8
|
22.2
|
19.8
|
23.2
|
26.3
|
Capex / Sales
|
4.05%
|
8.66%
|
-
|
3.03%
|
7.68%
|
7.05%
|
7.22%
|
7.29%
|
Announcement Date
|
3/10/20
|
3/4/21
|
2/23/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
21.87
USD Average target price
26.67
USD Spread / Average Target +21.93% Consensus |
1st Jan change
|
Capi.
|
---|
| -24.35% | 636M | | -18.17% | 8.55B | | +87.40% | 4.63B | | +16.31% | 2.98B | | -3.15% | 2.65B | | -2.10% | 1.89B | | -53.27% | 1.81B | | -12.97% | 1.56B | | +21.59% | 1.27B | | -47.96% | 1.07B |
Medical & Diagnostic Laboratories
|